美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Direxion Daily Biotech Top 5 Bull 2X ETF

38.29

-1.0161-2.59%

盤後：38.290.00000.00%16:10 EDT

成交量：1.70萬

成交額：65.82萬

市值：287.17萬

市盈率：- -

高：38.92

開：38.30

低：38.23

收：39.31

52周最高：45.88

52周最低：25.71

股本：7.50萬

流通股本：7.50萬

量比：1.08

換手率：22.73%

股息：0.62

股息率：1.62%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

港股早評：三大指數高開逾1.1%，生物科技股、黃金股大漲

AI生物科技股Twist Bioscience升逾22%

福泰製藥(VRTX)股票8月19日收盤上漲4.48%：釋放什麼信號？

TradingKey中文

吉利德科學(GILD)股票8月19日盤中上漲3.66%：背後推手曝光

TradingKey中文

安進(AMGN)股票8月19日盤中上漲3.19%：背後推手曝光

TradingKey中文

再生元製藥旗下Pasatru獲歐洲藥品管理局審評，全球申報在即

再生元製藥獲FDA批准：Pasatru（Garetosmab-Grts）上市，治療成人進行性骨化性纖維發育不良

受利好消息提振，美股生物科技股普漲

瑞穗上調安進目標價至352美元

藥代違規進入診療區域！湘雅二醫院發藥品「停用函」，艾力斯、賽諾菲、安進、康蒂尼四藥企上「黑榜」

TScan Therapeutics披露：安進將終止與其研究合作及許可協議

吉利德科學(GILD)股票8月18日盤中上漲3.14%：背後推手曝光

TradingKey中文

深圳易慕峯生物科技股份有限公司向港交所提交IPO申請，華泰金融控股（香港）為保薦人兼整體協調人。

argenx SE(ARGX)股票8月17日盤中上漲16.67%：關鍵驅動因素揭曉

TradingKey中文

EyePoint股價料將創下歷史最大跌幅，因其一款實驗性眼科藥物未能達到後期臨床試驗目標

美股開盤 | 三大指數升跌不一，閃迪升逾3%，Argenx SE漲近9%

老虎资讯综合

EyePoint公司治療年齡相關性眼病的藥物晚期臨床試驗失敗，股價暴跌

美股異動 | Argenx(ARGX.US)盤前升逾10% 自身免疫性肌炎藥物Vyvgart III期研究達主要終點

美股異動丨Argenx SE盤前大升逾7%，Efgartigimod治療肌炎III期試驗成功

步長製藥：控股子公司藥品臨床試驗申請獲受理，研發投入約3175.45萬元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/hant/stock/TBXU/news?page=4"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"TBXU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TBXU\",,,,,undefined,":{"symbol":"TBXU","market":"US","secType":"STK","nameCN":"Direxion Daily Biotech Top 5 Bull 2X ETF","latestPrice":38.289,"timestamp":1789502400000,"preClose":39.3051,"halted":0,"volume":17045,"hourTrading":{"tag":"盘后","latestPrice":38.289,"preClose":38.289,"latestTime":"16:10 EDT","volume":6,"amount":229.55597999999998,"timestamp":1789503007596,"change":0,"changeRate":0,"amplitude":0.002324},"delay":0,"changeRate":-0.025851607043360824,"floatShares":75001,"shares":75001,"eps":0,"marketStatus":"盤後交易","change":-1.0161,"latestTime":"09-15 17:41:38 EDT","open":38.3,"high":38.92,"low":38.225,"amount":658181,"amplitude":0.017682,"askPrice":57.33,"askSize":200,"bidPrice":19.37,"bidSize":200,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789516800000},"marketStatusCode":4,"adr":0,"exchange":"ARCA","adjPreClose":39.3051,"sharesOutstanding":100001,"nav":38.336,"aum":2875239.83,"dividendRate":0.01624,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":38.289,"preClose":38.289,"latestTime":"16:10 EDT","volume":6,"amount":229.55597999999998,"timestamp":1789503007596,"change":0,"changeRate":0,"amplitude":0.002324},"volumeRatio":1.076168},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TBXU\",,,,,undefined,":{"symbol":"TBXU","floatShares":75001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.076168,"shares":75001,"dividePrice":0.6218,"high":38.92,"amplitude":0.017682,"preClose":39.3051,"low":38.225,"week52Low":25.71,"pbRate":"--","week52High":45.88,"institutionHeld":0,"latestPrice":38.289,"eps":0,"divideRate":0.01624,"volume":17045,"delay":0,"ttmEps":0,"open":38.3,"prevYearClose":31.065,"prevWeekClose":38.3601,"prevMonthClose":42.9245,"prevQuarterClose":32.1223,"fiveDayClose":40.6496,"twentyDayClose":40.3209,"sixtyDayClose":29.86},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TBXU\",params:#limit:5,,,undefined,":[{"date":"2026-06-23","symbol":"TBXU","amount":0.11101,"announcedDate":"2026-06-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-23","defaultRemindTime":1782221400000,"name":"Direxion Daily Biotech Top 5 Bull 2X ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-30","payableDate":"2026-06-23","currency":"USD","dateTimestamp":1782187200000,"payDate":"2026-06-30"},{"date":"2026-03-24","symbol":"TBXU","amount":0.09893,"announcedDate":"2026-03-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-24","defaultRemindTime":1774359000000,"name":"Direxion Daily Biotech Top 5 Bull 2X ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-31","payableDate":"2026-03-24","currency":"USD","dateTimestamp":1774324800000,"payDate":"2026-03-31"},{"date":"2025-12-23","symbol":"TBXU","amount":0.10111,"announcedDate":"2025-12-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-23","defaultRemindTime":1766500200000,"name":"Direxion Daily Biotech Top 5 Bull 2X ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-31","payableDate":"2025-12-23","currency":"USD","dateTimestamp":1766466000000,"payDate":"2025-12-31"},{"date":"2025-12-10","symbol":"TBXU","amount":0.31143,"announcedDate":"2025-12-09","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-10","defaultRemindTime":1765377000000,"name":"Direxion Daily Biotech Top 5 Bull 2X ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-17","payableDate":"2025-12-10","currency":"USD","dateTimestamp":1765342800000,"payDate":"2025-12-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TBXU\",market:\"US\",,,undefined,":[{"executeDate":"2025-12-10","recordDate":"2025-12-10","paymentDate":"2025-12-17","value":0.31143,"currency":"USD"},{"executeDate":"2025-12-23","recordDate":"2025-12-23","paymentDate":"2025-12-31","value":0.10111,"currency":"USD"},{"executeDate":"2026-03-24","recordDate":"2026-03-24","paymentDate":"2026-03-31","value":0.09893,"currency":"USD"},{"executeDate":"2026-06-23","recordDate":"2026-06-23","paymentDate":"2026-06-30","value":0.11101,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TBXU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TBXU\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660472972","title":"港股早評：三大指數高開逾1.1%，生物科技股、黃金股大漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2660472972","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660472972?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 09:37","pubTimestamp":1787189821,"startTime":"0","endTime":"0","summary":"美股止住三连跌，日韩股市大幅反弹。港股三大指数集体高开，恒指涨1.11%，国指涨1.27%，恒生科技指数涨1.69%。大型科网股全线上涨，京东涨近3%，美团、阿里巴巴涨2%，腾讯、小米、百度皆上涨；mRNA肿瘤疫苗三期大获成功，全产业链迎来价值重估，生物医药股大涨，康希诺生物、云顶新耀大涨15%，金斯瑞生物科技大涨13%，金价大涨，黄金股领衔有色金属股上涨，另外，消费电子股、海运股、煤炭股部分走低。(格隆汇)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260820/32340660.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["GLDW","BK4588","TBXU","BIOY","159562","BK4585","VXUS","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660476170","title":"AI生物科技股Twist Bioscience升逾22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660476170","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660476170?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 06:26","pubTimestamp":1787178401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["TBXU","AGIX","BIOY","ARTY","AIPO","VTHR","QTOC","CHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660473644","title":"福泰製藥(VRTX)股票8月19日收盤上漲4.48%：釋放什麼信號？","url":"https://stock-news.laohu8.com/highlight/detail?id=2660473644","media":"TradingKey中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660473644?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 04:16","pubTimestamp":1787170582,"startTime":"0","endTime":"0","summary":"• 在竞争对手临床试验宣告失败后，福泰制药股价飙升至历史新高。\n• 第二季度营收超出预期，公司同时上调了全年业绩指引。\n• 分析师纷纷给出看涨评级，平均目标价达 563.25 美元。","market":"other","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262119125-market-movers-vrtx-20260819","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2236285917.USD","IE00BFTCPJ56.SGD","PBE","BK4139","LU1778281490.HKD","IE0002270589.USD","IE00B19Z3581.USD","LU0234570918.USD","LU1093756325.SGD","IE00B19Z3B42.SGD","IE00B19Z9P08.USD","LU2456880835.USD","SG9999001176.SGD","LU0289739699.SGD","TBXU","LU2237438978.USD","BK4588","IBB","LU2362541513.USD","GNMX","LU2462157665.USD","LU2468319806.SGD","LU0079474960.USD","LU0432979614.USD","LU1035775433.USD","IDNA","VRTX","IE00B4R5TH58.HKD","LU0058720904.USD","LU1585245621.USD","IBBQ","LU2417539215.USD","SGXZ57979304.SGD","BIB","LU1674673691.USD","LU0256863811.USD","BK4532","IE00B19Z9Z06.USD","LU0320765992.SGD","BBH","BK4567","LU0109394709.USD","LU2324357040.USD","LU1674673428.USD","LU2362541273.HKD","LU1069344957.HKD","IE00BJT1NW94.SGD","LU0417517546.SGD","LU0823416689.USD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660113478","title":"吉利德科學(GILD)股票8月19日盤中上漲3.66%：背後推手曝光","url":"https://stock-news.laohu8.com/highlight/detail?id=2660113478","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660113478?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 03:17","pubTimestamp":1787167048,"startTime":"0","endTime":"0","summary":"• 得益于HIV产品组合增长加速，吉利德上调了全年销售指引。\n• 联邦法院颁布禁令阻止海外进口，以保护其核心市场份额。\n• 分析师给予“买入”评级，平均目标价为157.79美元。","market":"nz","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262118864-market-movers-gild-20260819","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1674673428.USD","GILD","LU0965509101.SGD","LU0234570918.USD","LU2468319806.SGD","BBH","SG9999015952.SGD","SG9999015986.USD","LU1839511570.USD","LU1037948541.HKD","TMED","IE00B19Z3B42.SGD","LU0965509010.AUD","LU2324357040.USD","BK4139","IBBQ","IE00B7SZLL34.SGD","TBXU","IE0002270589.USD","LU0965508806.USD","LU1023059063.AUD","IE00BZ1G4Q59.USD","BIB","MEDI","IE00BSNM7G36.USD","LU1934455277.USD","LU0058720904.USD","BK4588","BK4550","LU1934455863.HKD","IE00BKVL7J92.USD","LU1057294990.SGD","IBB","SG9999015945.SGD","LU0320765992.SGD","SG9999015978.USD","IE00B19Z3581.USD","BK4568","LU0289739699.SGD","LU1778281490.HKD","LU1934455194.USD","BK4532","LU1585245621.USD","LU1674673691.USD","BK4583","LU1066051498.USD","BK4578","BMED","LU0965509283.SGD","LU0823416689.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660819420","title":"安進(AMGN)股票8月19日盤中上漲3.19%：背後推手曝光","url":"https://stock-news.laohu8.com/highlight/detail?id=2660819420","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660819420?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 02:16","pubTimestamp":1787163383,"startTime":"0","endTime":"0","summary":"• Argus上调安进目标价，并重申“买入”评级。\n• 第二季度财务业绩超出华尔街的营收和盈利预期。\n• 技术指标显示 MACD 买入信号及 RSI 买入条件。","market":"nz","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262118749-market-movers-amgn-20260819","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1061106388.HKD","IE00BJJMRZ35.SGD","LU1023059063.AUD","LU0868494617.USD","BK4139","LU1571399168.USD","IE00BJT1NW94.SGD","TBXU","LU1983299246.USD","LU0289739699.SGD","BK4533","IE00BFTCPJ56.SGD","BBH","BIB","BK4534","IE00B4R5TH58.HKD","LU0122379950.USD","IE0002141913.USD","LU2089984988.USD","PBE","BK4566","IBB","BK4599","IBBQ","IE00B2B36J28.USD","LU0320765992.SGD","IE0009355771.USD","BK4585","SG9999001440.SGD","LU1057294990.SGD","LU0889565916.HKD","LU2112291526.USD","LU2242652126.USD","LU2242646821.SGD","BK4588","PJP","LU0109394709.USD","BK4581","LU0058720904.USD","LU2468319806.SGD","AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105025052","title":"再生元製藥旗下Pasatru獲歐洲藥品管理局審評，全球申報在即","url":"https://stock-news.laohu8.com/highlight/detail?id=1105025052","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105025052?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 02:00","pubTimestamp":1787162410,"startTime":"0","endTime":"0","summary":"再生元制药公司宣布，其研发的药物Pasatru已被欧洲药品管理局纳入审评流程。与此同时，该公司正积极筹备在全球范围内提交该药物的上市申请。欧洲药品管理局的审评启动，为这款药物在欧洲地区的获批前景增添了重要砝码。业界分析认为，Pasatru若能顺利通过审评，有望为相关疾病领域带来新的治疗选择。再生元制药在创新药物研发领域深耕多年，此次针对Pasatru的全球布局，也彰显了其对这一候选药物商业潜力的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","LU0053666078.USD","LU2362540622.SGD","LU0109394709.USD","LU1917777945.USD","LU0823434740.USD","LU2362541273.HKD","LU0320765992.SGD","LU0289739699.SGD","LU2468319806.SGD","LU2106854487.HKD","LU2362541513.USD","IBBQ","LU1974910355.USD","LU0882574055.USD","BK4588","LU2089984988.USD","TBXU","IBB","LU2023250504.SGD","BBH","BK4585","REGN","LU0058720904.USD","BK4139","LU0823434583.USD","LU0889565916.HKD","LU2237438978.USD","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188134905","title":"再生元製藥獲FDA批准：Pasatru（Garetosmab-Grts）上市，治療成人進行性骨化性纖維發育不良","url":"https://stock-news.laohu8.com/highlight/detail?id=1188134905","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188134905?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 01:59","pubTimestamp":1787162353,"startTime":"0","endTime":"0","summary":"再生元制药公司今日宣布，其研发的新药Pasatru已获得美国食品药品监督管理局的正式批准，用于治疗成人进行性骨化性纤维发育不良。这一罕见疾病此前一直缺乏有效的治疗手段，此次获批为患者带来了新的希望。FDA的此次批准基于多项临床研究数据，结果显示Pasatru在减缓异位骨化进展方面表现出显著疗效，且安全性可控。未来，再生元制药计划进一步拓展Pasatru的适应症范围，并探索其在其他相关疾病中的潜在应用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","LU2106854487.HKD","LU0058720904.USD","LU0109394709.USD","LU1974910355.USD","LU1917777945.USD","LU0889565916.HKD","LU0823416689.USD","LU0320765992.SGD","LU2023250504.SGD","LU2362540622.SGD","IBBQ","LU0289739699.SGD","BK4139","BBH","IBB","TBXU","LU0053666078.USD","LU2362541513.USD","BK4588","REGN","LU0823434583.USD","LU0114720955.EUR","LU2362541273.HKD","BK4585","LU2089984988.USD","LU0823434740.USD","LU2237438978.USD","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660447273","title":"受利好消息提振，美股生物科技股普漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2660447273","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660447273?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 19:21","pubTimestamp":1787138473,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["TBXU","BIOY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660585446","title":"瑞穗上調安進目標價至352美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660585446","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660585446?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 16:55","pubTimestamp":1787129710,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4581","BK4588","LU2242646821.SGD","IE0002141913.USD","LU2242652126.USD","UUP","IE00BJJMRZ35.SGD","LU0289739699.SGD","UDN","BBH","BIB","TBXU","IE00B4R5TH58.HKD","LU1983299246.USD","BK4533","BK4599","LU2089984988.USD","LU0889565916.HKD","LU0058720904.USD","BK4534","LU0868494617.USD","IE00BJT1NW94.SGD","PJP","IBBQ","LU0109394709.USD","LU0122379950.USD","PBE","LU2468319806.SGD","BK4139","LU1023059063.AUD","LU1057294990.SGD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","LU1571399168.USD","IBB","SG9999001440.SGD","IE0009355771.USD","LU0320765992.SGD","AMGN","BK4585","LU2112291526.USD","BK4566","LU1061106388.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660416851","title":"藥代違規進入診療區域！湘雅二醫院發藥品「停用函」，艾力斯、賽諾菲、安進、康蒂尼四藥企上「黑榜」","url":"https://stock-news.laohu8.com/highlight/detail?id=2660416851","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660416851?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 09:48","pubTimestamp":1787104101,"startTime":"0","endTime":"0","summary":"湘雅二医院方面向澎湃新闻表示，院方确有发该“协办函”。据此次公布的协办函，对几家涉事药企的处理决定颇为严厉。近年来，医药代表违规已不仅是行业道德问题，而是监管重点。此次湘雅二医院将企业列入购销负面清单，正是医院端落地上述政策的缩影。湘雅二医院相关负责人表示，自国家在2020年底建立医药代表备案制度，医院就积极响应国家政策，并不断完善内部制度和执行流程。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1787103396417327872","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["IBB","BK4588","BK4581","LU0320765992.SGD","AMGN","LU2242646821.SGD","IE00B4R5TH58.HKD","LU2112291526.USD","LU1571399168.USD","LU0109394709.USD","LU2242652126.USD","BK4534","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU0289739699.SGD","BBH","LU2089984988.USD","BK4566","LU2468319806.SGD","LU1057294990.SGD","688578","BK4533","BK0239","TBXU","BIB","LU1023059063.AUD","IE00BJJMRZ35.SGD","LU0058720904.USD","BK4599","LU0889565916.HKD","IE0009355771.USD","BK4585","PJP","LU1983299246.USD","IBBQ","IE00B2B36J28.USD","LU0868494617.USD","SG9999001440.SGD","IE0002141913.USD","LU0122379950.USD","LU1061106388.HKD","PBE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192416297","title":"TScan Therapeutics披露：安進將終止與其研究合作及許可協議","url":"https://stock-news.laohu8.com/highlight/detail?id=1192416297","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192416297?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 05:04","pubTimestamp":1787087050,"startTime":"0","endTime":"0","summary":"值得注意的是，安进作为全球领先的生物制药公司，此举无疑将对TScan Therapeutics的研发管线及未来战略布局产生深远影响。TScan Therapeutics方面表示，将仔细评估这一变化对公司在研项目及整体运营带来的潜在影响。对于TScan Therapeutics而言，此番变故或许意味着需要重新校准其研发路径，并探索新的合作机会或资金来源以继续推进其创新疗法的开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","BK4588","BK4566","LU2242646821.SGD","IE00BJJMRZ35.SGD","AMGN","IE00BFTCPJ56.SGD","PBE","BK4534","LU0289739699.SGD","LU1571399168.USD","SG9999001440.SGD","LU0868494617.USD","LU1023059063.AUD","IE0009355771.USD","LU2089984988.USD","LU1057294990.SGD","LU0109394709.USD","BK4533","IE0002141913.USD","BK4599","LU2112291526.USD","TBXU","LU2242652126.USD","LU2468319806.SGD","IBB","IE00B4R5TH58.HKD","LU1061106388.HKD","BK4139","PJP","BK4539","BIB","IBBQ","BK4581","LU1983299246.USD","TCRX","LU0122379950.USD","BK4585","LU0058720904.USD","BBH","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660491619","title":"吉利德科學(GILD)股票8月18日盤中上漲3.14%：背後推手曝光","url":"https://stock-news.laohu8.com/highlight/detail?id=2660491619","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660491619?lang=zh_tw&edition=fundamental","pubTime":"2026-08-19 02:16","pubTimestamp":1787076999,"startTime":"0","endTime":"0","summary":"• 联邦法院禁令阻止了吉利德关键HIV药物的海外进口。\n• 强劲的基础业务营收增长与上调业绩指引提振了市场乐观情绪。\n• 肿瘤领域的战略投资及机构看涨期权活动的活跃支撑了股价的上涨势头。","market":"sh","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262115765-market-movers-gild-20260818","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2112291526.USD","LU1585245621.USD","BMED","LU1037948897.HKD","LU1430594728.SGD","LU1037948541.HKD","IE00BKVL7J92.USD","TBXU","LU1571399168.USD","LU0320765992.SGD","LU1674673691.USD","LU2324357040.USD","BK4583","SG9999015986.USD","IE00B19Z3B42.SGD","IE00B19Z3581.USD","LU1061106388.HKD","BK4585","LU0058720904.USD","LU1023059063.AUD","BK4532","LU1839511570.USD","LU0289739699.SGD","TMED","LU2087621335.USD","LU1934455863.HKD","IE00BSNM7G36.USD","LU0965508806.USD","MEDI","LU0109394709.USD","LU1066053197.SGD","SG9999015978.USD","IBBQ","LU1778281490.HKD","BK4550","IBB","BK4566","LU0114720955.EUR","SG9999015952.SGD","IE00BZ1G4Q59.USD","LU0823416689.USD","BK4578","LU1674673428.USD","LU0965509101.SGD","LU2089984988.USD","IE00B7SZLL34.SGD","IE00B3T34201.USD","BIB","BBH","GILD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660304824","title":"深圳易慕峯生物科技股份有限公司向港交所提交IPO申請，華泰金融控股（香港）為保薦人兼整體協調人。","url":"https://stock-news.laohu8.com/highlight/detail?id=2660304824","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660304824?lang=zh_tw&edition=fundamental","pubTime":"2026-08-18 07:26","pubTimestamp":1787009193,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["FRHC","IPOS","REDS","KCE","TBXU","BIOY","BK4127","159940"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660439442","title":"argenx SE(ARGX)股票8月17日盤中上漲16.67%：關鍵驅動因素揭曉","url":"https://stock-news.laohu8.com/highlight/detail?id=2660439442","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660439442?lang=zh_tw&edition=fundamental","pubTime":"2026-08-18 00:16","pubTimestamp":1786983373,"startTime":"0","endTime":"0","summary":"• Argenx 宣布其药物 VYVGART Hytrulo 在治疗肌炎的 3 期 ALKIVIA 研究中取得积极结果。\n• 该公司公布全年营收为 41.5 亿美元，净利润为 12.9 亿美元。\n• 分析师给予“买入”评级，平均目标价为 1083.77 美元。","market":"sg","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262112725-market-movers-argx-20260817","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","IE0034235188.USD","IE0002141913.USD","ARGX","FMED","LU2324357040.USD","BK4139","LU1983260115.SGD","BK4505","LU0889565916.HKD","BK4585","IBB","LU0109394709.USD","IE00BFTCPJ56.SGD","IE0009355771.USD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU0823416689.USD","IE00BJJMRZ35.SGD","TBXU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660332334","title":"EyePoint股價料將創下歷史最大跌幅，因其一款實驗性眼科藥物未能達到後期臨床試驗目標","url":"https://stock-news.laohu8.com/highlight/detail?id=2660332334","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660332334?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 22:15","pubTimestamp":1786976114,"startTime":"0","endTime":"0","summary":"BUZZ-EyePoint股价料将创下历史最大跌幅，因其一款实验性眼科药物未能达到后期临床试验目标最新动态8月17日-**EyePoint公司（EYPT.O）股价暴跌71%至4.17美元，有望创下有史以来最大单日跌幅，并跌至2025年4月以来的最低点**这家药物开发商表示，其实验性眼科药物Duravyu在针对湿性年龄相关性黄斑变性（视力丧失的主要原因之一）患者开展的晚期临床试验中，未能达到主要目标","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nL4T44E101:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2468319806.SGD","LU2089984988.USD","LU2362541273.HKD","IBB","REGN","LU1974910355.USD","LU0823416689.USD","EYPT","LU0058720904.USD","LU0823434740.USD","LU0823434583.USD","LU2362541513.USD","LU0320765992.SGD","LU0109394709.USD","LU2362540622.SGD","BK4588","LU0882574055.USD","LU2237438978.USD","BK4007","LU0289739699.SGD","LU0889565916.HKD","LU2106854487.HKD","BK4139","BBH","BK4585","TBXU","IBBQ","LU0053666078.USD","LU0114720955.EUR","LU1917777945.USD","LU2023250504.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137019504","title":"美股開盤 | 三大指數升跌不一，閃迪升逾3%，Argenx SE漲近9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1137019504","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137019504?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 21:32","pubTimestamp":1786973544,"startTime":"0","endTime":"0","summary":"8月17日，美股三大指数开盘涨跌不一，道琼斯指数跌0.23%，标普500指数涨0.04%，纳斯达克综合指数涨0.24%。美股存储股普涨，SK海力士、西部数据、闪迪涨超3%，美光科技、希捷科技涨超2%。OmniAb涨超23%，公司此前宣布与礼来达成3.7亿美元药物研发协议。Argenx SE涨近9%，Efgartigimod治疗肌炎III期试验成功。","market":"us","thumbnail":"https://static.tigerbbs.com/ff6e3231d788a5a6d28cf7965385cc7f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/ff6e3231d788a5a6d28cf7965385cc7f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4543","ARTY","SKHY","SKHU","LU0689472784.USD","LU2361044865.SGD","SNXX","BK4505","LU0471298777.SGD","SNDK","EMSF","LU2491050071.SGD","CHPX","LU1917777945.USD","MEDI","LU1127390331.HKD","MU","LU2286300806.USD","UDOW","LU1093756168.USD","IE0009355771.USD","DIA","SNDQ","LU0957808578.USD","LU0082616367.USD","LU0203347892.USD","THNR","LU2324357040.USD","MEDX","IE00B19Z3B42.SGD","LU1035775433.USD","LU2756315664.SGD","SKDD","VHT","LU0256863811.USD","CNEQ","LU1804176565.USD","BK4527","LU0198837287.USD","FTXH","OZEM","LU0820561818.USD","BK4554","SPXU","BK4575","AGNG","FSMD","LU2237438978.USD","LU1868836591.USD","LU0006061336.USD","IXN","DMAX","LU1551013342.USD","LU1057294990.SGD","SKHYV","LU2458330169.SGD","LU2102340556.USD","LU0056508442.USD","IE00BJJMRX11.SGD","TBXU","SNDU","LU1235294995.USD","LU0640476718.USD","LU2458330243.SGD","LU2552382132.HKD","LU1366192091.USD","CHAT","LU2250418816.HKD","DXD","LU1035773651.USD","LU1674673428.USD","VOO","IE00B5949003.HKD","LU2746668461.USD","FMED","LU0058720904.USD","LU2237443382.USD","BK4599","XNTK","SHOC","LU0096364046.USD","LU0320765059.SGD","LU0174119429.USD","SKHZ","LU0109392836.USD","SOXQ","SKHX","LU2265009873.SGD","LU1868837300.USD","LU2237443978.SGD","LU0006306889.USD","SGXZ99366536.SGD","LU0642271901.SGD","LU1868836757.USD","LU2461242641.AUD","LU1316542783.SGD","LU1629891620.HKD","BK4512","IE00BN29S564.USD","LU2106854487.HKD","VGT","LU2048586759.USD","BK4170","ELIL","LU0353189763.USD","LU2756315318.SGD","LU0320765992.SGD","LU2023251221.USD","LU1145028129.USD",".DJI","LU2543165471.USD","LU1291159041.SGD","IE0034235303.USD","LU1267930730.SGD","IE0002141913.USD","AIS","LU2360106780.USD","SNDC","LU1712237335.SGD","LU0238689110.USD","IE00B7KXQ091.USD","LU1988902786.USD","LU2750360641.GBP","LU0444971666.USD","LU0466842654.USD","LU0094547139.USD","IHE","LU2168563687.JPY","LU0385154629.USD","IE00B7SZLL34.SGD","SG9999017495.SGD","LU2168564222.USD","SGXZ81514606.USD","IE00BFSS7M15.SGD","LU0162691827.USD","IE0034235188.USD","LU0054578231.USD","LU0792757196.USD","SGXZ51526630.SGD","LU2054465674.USD","LU0859254822.USD","LU0154236417.USD","SG9999014880.SGD","SKHA","DOG","IE00B4R5TH58.HKD","LU2168564149.EUR","LU2361044949.HKD","SPXS","LU0882574055.USD","FXL","WLDR","LU0266013472.USD","IVV","LU0820561909.HKD","JDOC","IXJ","LU2237443895.HKD","LU0823434583.USD","LU2360107168.USD","LU0345770308.USD","LU2552382058.USD","BK4007","BK4141","LU0109391861.USD","BAI","SG9999001176.USD","SG9999015986.USD","LU1868837136.USD","BK4534","LU0274383776.USD","SPYH","SG9999018865.SGD","MHIP","SPYU","LU2357305700.SGD","DDM","MIC","IBB","LU0889566641.SGD","LU1823568750.SGD","LU1914381329.SGD","LU2236285917.USD","IE00BKPKM429.USD","LU0157215616.USD","LU1069344957.HKD","LU0225283273.USD","LLYX","SPUU","CHPS","LU1979441026.SGD","LU2491050154.USD","LU1989764664.SGD","LU0122379950.USD","LU2471134879.HKD","SG9999014906.USD","IE00BFTCPJ56.SGD","LU2089284900.SGD","LU2237443465.HKD","SG9999014914.USD","LU0417517546.SGD","LU2746668974.SGD","SH","LU1868836914.USD","ARGX","QQQA","LU1852331112.SGD","LU0964807845.USD","LU2237443622.USD","MUZ","SG9999013999.USD","SG9999015952.SGD","LU2168564495.EUR","LU2087625088.SGD","LU0203201768.USD","LU1720051017.SGD",".SPX","IE00BWXC8680.SGD","HYNX","LU2023250330.USD","LU0683600562.USD",".IXIC","SG9999001424.SGD","LU0823434740.USD","LU1551013425.SGD","LEGR","DISK","TTXU","LU2602419157.SGD","LU0719512351.SGD","BK4581","SDOW","STX","IE0005OL40V9.USD","LU0109394709.USD","MUYY","SG9999015978.USD","FHLC","LU1814569148.SGD","WDCX","IE00B2B36J28.USD","LLII","HRTS","TRFK","LU0432979614.USD","LU2063271972.USD","LU1989764748.USD","LU0240877869.USD","LU0672654240.SGD","LU0456855351.SGD","BK7142","LU1803068979.SGD","IE0009356076.USD","LU0158827781.USD","LU0786609619.USD","LU0127658192.USD","XLK","HIBL","LU0081259029.USD","IE00BK4W5M84.HKD","LU1366333091.USD","IE00B19Z9P08.USD","TMED","LU2357627491.SGD","LU0963586101.USD","LU1046421795.USD","LU2361045086.USD","SCHA","PPH","SMAX","IE00BJT1NW94.SGD","LU0323591593.USD","LU2471134796.USD","IE00BK4W5L77.USD","LU0061475181.USD","LU2112291526.USD","LU0240878834.USD","FTEC","IETC","LU2360106947.USD","LU1093756325.SGD","FAI","BK4579","MUD","SPXL","LU1061106388.HKD","SGXZ31699556.SGD","LU0476273544.USD","LU1674673691.USD","GB00BDT5M118.USD","SG9999015945.SGD","LU0787776722.HKD","LU1023059063.AUD","SG9999001176.SGD","IE00B4JS1V06.HKD","SDS","LU0889565833.HKD","AIQ","BK4585","EFIV","IE00BJLML261.HKD","LU1280957306.USD","LU0256863902.USD","IE00BKDWB100.SGD","SSO","FCUS","LU0203202063.USD","LU0079474960.USD","MMAX","LU2491049909.HKD","SPDN","PTF","LU2023250504.SGD","WDC","LU2211815571.USD","ELIS","LU2471134523.USD","SPYQ","IE00BSNM7G36.USD","LU1778281490.HKD","LU0210536198.USD","LU2108987350.USD","IE0004445015.USD","LU2471134952.CNY","LU0354030438.USD","IE00B1BXHZ80.USD","IE00B1XK9C88.USD","LU1720051108.HKD","IE00B19Z9Z06.USD","RULE","LU2111349929.HKD","SG9999014898.SGD","QQQG","HBMX","LU0133085943.USD","LU2750360997.AUD","LU2462157665.USD","LU0158827948.USD","IE00BFSS8Q28.SGD","LU0708995401.HKD","SCHM","LU0234572021.USD","LU0289739699.SGD","BK4566","LU1861215975.USD","WDNA","07709","IE0002270589.USD","WUGI","LU1983260115.SGD","LLY","IE00B775H168.HKD","LU0820562030.AUD","LU2089985449.USD","BK4553","BK4516","IE0001KFT4U8.USD","LU1323610961.USD","LU2468319806.SGD","PJP","LU2264538146.SGD","SG9999018857.SGD","LU0072461881.USD","BK4588","LU0823416689.USD","LU0889565916.HKD","USXF","LU2462591350.SGD","FTXL","YMmain","CNAV","SPYM","LU2290526834.HKD","LU1642822529.SGD","LU1064131342.USD","IE0004445239.USD","BOBP","LU1983299246.USD","YSPY","LU1861220033.SGD","LU1670627923.USD","LU2168564065.EUR","ILDR","LU2089283258.USD","LU2028103732.USD","LU1623119135.USD","LU2896262040.SGD","BK4139","SGXZ57979304.SGD","LU1974910355.USD","IE00B894F039.SGD","LU2089984988.USD","RXL","BK4533","LU0354030511.USD","LU0353189680.USD","SPY","BK4532","SOXX","SNDG","SKUU","LU0097036916.USD","LU0203345920.USD","CURE","MULL","LU1815336760.USD","LU2456880835.USD","COWG","LU0106261372.USD","LU2271345857.HKD","TRUH","TMSL","LU0444973449.USD","LU1670628061.USD","LU0943347566.SGD","XLV","SK","BK4605","LU1548497426.USD","LU0345770993.USD","LU1989771016.USD","LU2417539215.USD","LU2403377893.USD","GDOC","LU0882574139.USD","STX.AU","MUU","AIFD","LU0316494557.USD","OPTZ","CANC","IYH","LU1232071149.USD","LU1069347547.HKD","LU2213496289.HKD","LU1267930813.SGD","SMH","LU0114720955.EUR","UPRO","LLYZ","JGRO","LU0471298694.HKD","IE00B19Z3581.USD","SMU00main","IE000M9KFDE8.USD","CGGO","IE00BJJMRY28.SGD","LU2552382215.SGD","PSI","FDTX","EGGY","LU2931357623.SGD","IE00BJJMRZ35.SGD","LU2237443549.SGD","DRMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660848445","title":"EyePoint公司治療年齡相關性眼病的藥物晚期臨床試驗失敗，股價暴跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2660848445","media":"路透中文","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660848445?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 19:14","pubTimestamp":1786965255,"startTime":"0","endTime":"0","summary":"EyePoint公司未能证明Duravyu在保护视力方面不比Eylea明显逊色。而在接受Eylea治疗的患者中，未出现此类情况。EyePoint的股价在早盘交易中跌至4.16美元。EyePoint计划于2027年上半年向美国FDA提交批准申请，具体取决于预计于今年晚些时候公布的第二项晚期临床试验结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nL4T44E0O1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237438978.USD","BK4139","BK4585","LU0053666078.USD","LU1974910355.USD","LU2362541273.HKD","LU2468319806.SGD","IBB","LU2089984988.USD","TBXU","LU0114720955.EUR","LU0882574055.USD","BK4588","LU2362540622.SGD","LU2023250504.SGD","BBH","LU2362541513.USD","OTLK","LU2106854487.HKD","REGN","LU0889565916.HKD","IBBQ","LU0109394709.USD","LU0320765992.SGD","LU1917777945.USD","LU0823416689.USD","LU0289739699.SGD","LU0823434740.USD","EYPT","LU0823434583.USD","LU0058720904.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660481020","title":"美股異動 | Argenx(ARGX.US)盤前升逾10% 自身免疫性肌炎藥物Vyvgart III期研究達主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2660481020","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660481020?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 18:48","pubTimestamp":1786963699,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE0034235188.USD","FMED","IE0009355771.USD","BK4505","BK4588","IBB","LU0320765992.SGD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0109394709.USD","III","BK4139","IE00BJT1NW94.SGD","LU0889565916.HKD","BK4134","ARGX","BK4585","LU1983260115.SGD","TBXU","IE0002141913.USD","LU0823416689.USD","LU2324357040.USD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660848605","title":"美股異動丨Argenx SE盤前大升逾7%，Efgartigimod治療肌炎III期試驗成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2660848605","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660848605?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 17:37","pubTimestamp":1786959424,"startTime":"0","endTime":"0","summary":"Argenx SE(ARGX.US)盘前涨超7%，报913.38美元。消息面上，公司宣布，Efgartigimod在治疗自身免疫性肌炎的III期ALKIVIA试验中达到了主要终点。在52周时，与安慰剂相比，药物在总改善评分(TIS) 上实现了具有统计学和临床意义的改善。此次试验成功对Argenx意义重大，开辟新市场：自身免疫性肌炎在美国影响约10万人，其中IMNM约2万，DM约4万，这是一个尚未被满足的巨大医疗市场。公司计划为IMNM提交加速审批申请，并将与FDA讨论DM的申报可能性。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202608/17/20260817706794.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202608/17/20260817706794.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260817/32337291.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK4139","FMED","IE0009355771.USD","LU0823416689.USD","ARGX","IBB","LU0889565916.HKD","III","IE00BJT1NW94.SGD","BK4134","IE00B4R5TH58.HKD","IE0034235188.USD","BK4588","IE00BJJMRZ35.SGD","IE0002141913.USD","TBXU","BK4585","IE00BFTCPJ56.SGD","BK4505","IE00B2B36J28.USD","LU1983260115.SGD","LU0320765992.SGD","LU2324357040.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660648687","title":"步長製藥：控股子公司藥品臨床試驗申請獲受理，研發投入約3175.45萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660648687","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660648687?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 17:16","pubTimestamp":1786958196,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["NVOX","TBXU","NVOH"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":4,"totalSize":159,"code":"91000000","status":"200"}]}}